Abstract
Of the neurodegenerative diseases presented in this book, Huntington’s disease (HD) stands as the archetypal autosomal dominantly inherited neurodegenerative disorder. Its occurrence through generations of affected families was noted long before the basic genetic underpinnings of hereditary diseases was understood. The early classification of HD as a distinct hereditary neurodegenerative disorder allowed the study of this disease to lead the way in the development of our understanding of the mechanisms of human genetic disorders. Following its clinical and pathologic characterization, the causative genetic mutation in HD was subsequently identified as a trinucleotide (CAG) repeat expansion in the huntingtin (HTT) gene, and consequently, the HTT gene and huntingtin protein have been studied in great detail. Despite this concentrated effort, there is still much about the function of huntingtin that still remains unknown. Presented in this chapter is an overview of the current knowledge on the normal function of huntingtin and some of the potential neurobiologic mechanisms by which the mutant HTT gene may mediate neurodegeneration in HD.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Altar CA, Cai N, Bliven T et al (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856–860. doi:10.1038/39885
Andrade MA, Bork P (1995) HEAT repeats in the Huntington’s disease protein. Nat Genet 11:115–116. doi:10.1038/ng1095-115
Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4:398–403. doi:10.1038/ng0893-398
Arrasate M, Mitra S, Schweitzer ES et al (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810. doi:10.1038/nature02998
Bañez-Coronel M, Porta S, Kagerbauer B et al (2012) A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8:e1002481. doi:10.1371/journal.pgen.1002481
Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24:4250–4258. doi:10.1523/JNEUROSCI.3920-03.2004
Baxendale S, Abdulla S, Elgar G et al (1995) Comparative sequence analysis of the human and pufferfish Huntington’s disease genes. Nat Genet 10:67–76. doi:10.1038/ng0595-67
Bemelmans AP, Horellou P, Pradier L et al (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10:2987–2997. doi:10.1089/10430349950016393
Benchoua A, Trioulier Y, Zala D et al (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652–1663. doi:10.1091/mbc.E05-07-0607
Boutell JM, Thomas P, Neal JW et al (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington’s disease gene product, huntingtin. Hum Mol Genet 8:1647–1655
Canals JM, Pineda JR, Torres-Peraza JF et al (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci 24:7727–7739. doi:10.1523/JNEUROSCI.1197-04.2004
Chang DTW, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22:388–400. doi:10.1016/j.nbd.2005.12.007
Chattopadhyay B, Baksi K, Mukhopadhyay S, Bhattacharyya NP (2005) Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci Lett 374:81–86. doi:10.1016/j.neulet.2004.10.018
Chung DW, Rudnicki DD, Yu L, Margolis RL (2011) A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet 20:3467–3477. doi:10.1093/hmg/ddr263
Cowan CM, Fan MMY, Fan J et al (2008) Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 28:12725–12735. doi:10.1523/JNEUROSCI.4619-08.2008
Craufurd D, Snowden JS (2002) Neuropsychological and neuropsychiatric aspects of Huntington’s disease. In: Harper P, Bates G, Jones L (eds) Huntington’s disease, 3rd edn. Oxford University Press, Oxford, pp 62–94
Cui L, Jeong H, Borovecki F et al (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59–69. doi:10.1016/j.cell.2006.09.015
Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548
Desplats PA, Kass KE, Gilmartin T et al (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743–757. doi:10.1111/j.1471-4159.2005.03588.x
Djoussé L, Knowlton B, Hayden MR et al (2004) Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 5:109–114. doi:10.1007/s10048-004-0175-2
Dunah AW, Jeong H, Griffin A et al (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238–2243. doi:10.1126/science.1072613
Duyao MP, Auerbach AB, Ryan A et al (1995) Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269:407–410
Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17:475–492. doi:10.1177/1073858410390378
Feng Z, Jin S, Zupnick A et al (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25:1–7. doi:10.1038/sj.onc.1209021
Fernandes HB, Baimbridge KG, Church J et al (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27:13614–13623. doi:10.1523/JNEUROSCI.3455-07.2007
Fiszer A, Krzyzosiak WJ (2013) RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J Mol Med 91:683–691. doi:10.1007/s00109-013-1016-2
Gafni J, Ellerby LM (2002) Calpain activation in Huntington's disease. J Neurosci 22:4842–4849
Gafni J, Hermel E, Young JE et al (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279:20211–20220. doi:10.1074/jbc.M401267200
Gauthier LR, Charrin BC, Borrell-Pagès M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138. doi:10.1016/j.cell.2004.06.018
Gissi C, Pesole G, Cattaneo E, Tartari M (2006) Huntingtin gene evolution in Chordata and its peculiar features in the ascidian Ciona genus. BMC Genomics 7:288. doi:10.1186/1471-2164-7-288
Gladding CM, Sepers MD, Xu J et al (2012) Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum Mol Genet 21:3739–3752. doi:10.1093/hmg/dds154
Goldberg YP, Nicholson DW, Rasper DM et al (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13:442–449. doi:10.1038/ng0896-442
Gonitel R, Moffitt H, Sathasivam K et al (2008) DNA instability in postmitotic neurons. Proc Natl Acad Sci USA 105:3467–3472. doi:10.1073/pnas.0800048105
Graham RK, Pouladi MA, Joshi P et al (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29:2193–2204. doi:10.1523/JNEUROSCI.5473-08.2009
Gu M, Gash MT, Mann VM et al (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385–389. doi:10.1002/ana.410390317
Hedreen JC, Peyser CE, Folstein SE, Ross CA (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 133:257–261
Holzmann C, Schmidt T, Thiel G et al (2001) Functional characterization of the human Huntington's disease gene promoter. Brain Res Mol Brain Res 92:85–97
Huang K, Yanai A, Kang R et al (2004) Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron 44:977–986. doi:10.1016/j.neuron.2004.11.027
Humbert S, Bryson EA, Cordelières FP et al (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2:831–837
Huntington G (1872) On Chorea. Med Surg Rep 26:317–321
Imarisio S, Carmichael J, Korolchuk V et al (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412:191–209. doi:10.1042/BJ20071619
Jasinska A, Michlewski G, de Mezer M et al (2003) Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res 31:5463–5468
Johnson R, Zuccato C, Belyaev ND et al (2008) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 29:438–445. doi:10.1016/j.nbd.2007.11.001
Kalchman MA, Graham RK, Xia G et al (1996) Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 271:19385–19394
Lawlor KT, O’Keefe LV, Samaraweera SE et al (2011) Double-stranded RNA is pathogenic in Drosophila models of expanded repeat neurodegenerative diseases. Hum Mol Genet 20:3757–3768. doi:10.1093/hmg/ddr292
Leavitt BR, Guttman JA, Hodgson JG et al (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 68:313–324. doi:10.1086/318207
Leavitt BR, Van Raamsdonk JM, Shehadeh J et al (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96:1121–1129. doi:10.1111/j.1471-4159.2005.03605.x
Li L, Fan M, Icton CD et al (2003) Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 24:1113–1121
Li L, Murphy TH, Hayden MR, Raymond LA (2004) Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol 92:2738–2746. doi:10.1152/jn.00308.2004
Lin B, Rommens JM et al (1993) Differential 3′ polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Hum Mol Genet 2(10):1541–1545
Lin B, Nasir J, Kalchman MA et al (1995) Structural analysis of the 5′ region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics 25:707–715
Liot G, Zala D, Pla P et al (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33:6298–6309. doi:10.1523/JNEUROSCI.2033-12.2013
Luo S, Vacher C, Davies JE, Rubinsztein DC (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169:647–656. doi:10.1083/jcb.200412071
MacDonald ME, Vonsattel JP, Shrinidhi J et al (1999) Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease. Neurology 53:1330–1332
Mahant N, McCusker EA, Byth K et al (2003) Huntington’s disease: clinical correlates of disability and progression. Neurology 61:1085–1092
McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517–519
Mende-Mueller LM, Toneff T, Hwang SR et al (2001) Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington’s disease striatum. J Neurosci 21:1830–1837
Milakovic T, Quintanilla RA, Johnson GVW (2006) Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 281:34785–34795. doi:10.1074/jbc.M603845200
Mizuno K, Carnahan J, Nawa H (1994) Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 165:243–256. doi:10.1006/dbio.1994.1250
Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington’s disease. J Neurochem 76:166–172
Myers RH, Leavitt J, Farrer LA et al (1989) Homozygote for Huntington disease. Am J Hum Genet 45:615–618
Mykowska A, Sobczak K, Wojciechowska M et al (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res 39:8938–8951. doi:10.1093/nar/gkr608
Nasir J, Floresco SB, O’Kusky JR et al (1995) Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811–823
Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT (2003) In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington’s disease. Arch Biochem Biophys 410:1–6
Pineda JR, Canals JM, Bosch M et al (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington’s disease. J Neurochem 93:1057–1068. doi:10.1111/j.1471-4159.2005.03047.x
Pringsheim T, Wiltshire K, Day L et al (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 27:1083–1091. doi:10.1002/mds.25075
Reiner A, Dragatsis I, Zeitlin S, Goldowitz D (2003) Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 28:259–276. doi:10.1385/MN:28:3:259
Rigamonti D, Bauer JH, De-Fraja C et al (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705–3713
Rigamonti D, Sipione S, Goffredo D et al (2001) Huntingtin’s neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545–14548. doi:10.1074/jbc.C100044200
Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 110:2366–2370. doi:10.1073/pnas.1221891110
Schwarcz R, Foster AC, French ED et al (1984) Excitotoxic models for neurodegenerative disorders. Life Sci 35:19–32
Sheng M, Kim MJ (2002) Postsynaptic signaling and plasticity mechanisms. Science 298:776–780. doi:10.1126/science.1075333
Shimohata T, Nakajima T, Yamada M et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26:29–36. doi:10.1038/79139
Smith R, Petersén A, Bates GP et al (2005) Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiol Dis 20:673–684. doi:10.1016/j.nbd.2005.05.008
Sobczak K, de Mezer M, Michlewski G et al (2003) RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res 31:5469–5482
Spargo E, Everall IP, Lantos PL (1993) Neuronal loss in the hippocampus in Huntington’s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatr 56:487–491
Steffan JS, Kazantsev A, Spasic-Boskovic O et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97:6763–6768. doi:10.1073/pnas.100110097
Steffan JS, Agrawal N, Pallos J et al (2004) SUMO modification of Huntingtin and Huntington’s disease pathology. Science 304:100–104. doi:10.1126/science.1092194
Takano H, Gusella JF (2002) The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci 3:15
Tanaka K, Shouguchi-Miyata J, Miyamoto N, Ikeda J-E (2004) Novel nuclear shuttle proteins, HDBP1 and HDBP2, bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington’s disease gene. J Biol Chem 279:7275–7286. doi:10.1074/jbc.M310726200
Tartari M, Gissi C, Sardo Lo V et al (2008) Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 25:330–338. doi:10.1093/molbev/msm258
The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983
Van Raamsdonk JM, Pearson J, Rogers DA et al (2005a) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379–1392. doi:10.1093/hmg/ddi147
Van Raamsdonk JM, Pearson J, Slow EJ et al (2005b) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 25:4169–4180. doi:10.1523/JNEUROSCI.0590-05.2005
Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26:512–520. doi:10.1016/j.nbd.2007.01.006
Ventimiglia R, Mather PE, Jones BE, Lindsay RM (1995) The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 7:213–222
Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384
Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18:737–752. doi:10.1093/hmg/ddn404
Wang R, Luo Y, Ly PTT et al (2012) Sp1 regulates human huntingtin gene expression. J Mol Neurosci. doi:10.1007/s12031-012-9739-z
Warby SC, Chan EY, Metzler M et al (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14:1569–1577. doi:10.1093/hmg/ddi165
Warby SC, Montpetit A, Hayden AR et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84:351–366. doi:10.1016/j.ajhg.2009.02.003
Wellington CL, Ellerby LM, Hackam AS et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273:9158–9167
Wexler NS, Young AB, Tanzi RE et al (1987) Homozygotes for Huntington’s disease. Nature 326:194–197. doi:10.1038/326194a0
White JK, Auerbach W, Duyao MP et al (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17:404–410. doi:10.1038/ng1297-404
Xia J, Lee DH, Taylor J et al (2003) Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 12:1393–1403
Young FB, Butland SL, Sanders SS et al (2012) Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Prog Neurobiol 97:220–238. doi:10.1016/j.pneurobio.2011.11.002
Yu Z, Teng X, Bonini NM (2011) Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model for myotonic dystrophy. PLoS Genet 7:e1001340. doi:10.1371/journal.pgen.1001340
Zeitlin S, Liu JP, Chapman DL et al (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11:155–163. doi:10.1038/ng1095-155
Zhang Y, Li M, Drozda M et al (2003) Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 87:101–106
Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293:493–498. doi:10.1126/science.1059581
Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76–83. doi:10.1038/ng1219
Zuccato C, Belyaev N, Conforti P et al (2007) Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington’s disease. J Neurosci 27:6972–6983. doi:10.1523/JNEUROSCI.4278-06.2007
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
De Souza, R.A.G., Leavitt, B.R. (2014). Neurobiology of Huntington’s Disease. In: Nguyen, H., Cenci, M. (eds) Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Current Topics in Behavioral Neurosciences, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_353
Download citation
DOI: https://doi.org/10.1007/7854_2014_353
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46343-7
Online ISBN: 978-3-662-46344-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)